Semaglutide, a newly subcutaneous and long acting GLP-1 RA with 94% structural homology to native GLP-1, has been approved by the United States Food and Drug Administration (FDA) on December 5, 2017, as an adjunct to diet and exercise for the treatment of T2DM (Lau et al., 2015; Dhillon, 2018). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.